RCS - Frontier IP Group - Portfolio news - The Vaccine Group

Frontier IPAnnouncement

13/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231213:nRSM5618Wa&default-theme=true

RNS Number : 5618W  Frontier IP Group plc  13 December 2023

Reach - a non-regulatory announcement

AIM: FIPP

13 December 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - The Vaccine Group announces significant milestone in the
appointment of Advisory Board

 

 

 

Frontier IP, a specialist in commercialising intellectual property, notes the
following announcement that portfolio company The Vaccine Group ("TVG" or the
"Company") has appointed an Advisory Board to support scale-up of the
Company's novel herpesvirus-based vaccine platform.

 

The advisory board consists of three high-ranking veterinary experts with
strong business experience and connections to major companies and other
organisations in the animal health sector. The move reflects the progress TVG
has made in establishing a strong vaccine pipeline.

 

Neil Crabb, Frontier IP Chief Executive Officer, said: "I am delighted TVG has
been able to form an advisory group of such good quality. It is a testament to
the potential of the Company, its vaccine platform and pipeline, and I look
forward to further developments as TVG's vaccines move towards scale up and
full commercialisation. "

 

 

The Vaccine Group statement begins:

 

The Vaccine Group announces appointment of Advisory Board

 

The Vaccine Group ("TVG") has appointed three high-ranking and well-connected
animal health experts to form an advisory board to support scale up of the
Company's novel herpesvirus-based vaccine platform and to forge deeper
industry relationships.

 

TVG has made strong progress in establishing a pipeline of vaccines for use in
livestock, pets and wildlife to tackle a range of viral and bacterial
pathogens which cause severe economic harm or, if they are zoonotic, can also
pose a threat to human health.

 

The advisory board members have extensive veterinary health and business
experience. They are:

 

Christophe Barnier-Quer: Christophe works for Merck Life Science in its
Contract Development and Manufacturing Organisations branch. He has a PhD in
pharmaceutical science from Leiden University, an MBA from HEC Paris and 15
years' experience in vaccine R&D, including as R&D director for
GALVmed.

 

Johan Dreesen: A doctor in veterinary medicine, Johann runs an animal health
consultancy with a focus on start-ups, animal health pharmaceuticals and
non-government organisations. He is a member of the Advisory Council to Kela
Pharma and sits on the GALVmed board. He received his doctorate from Ghent
University and worked in veterinary practice before leading businesses within
Pfizer Animal Health and Zoetis.

 

Vaughn Kubiak: Vaughn has more than 40 years' experience in global animal
health in a wide range of senior technical and managerial roles in major
companies across R&D, quality assurance and quality control, regulatory
affairs, product management and commercial operations. Before retirement in
2019, he spent 17 years at Zoetis. Vaughn now works as a consultant and sits
on several technical advisory boards. He has a Master of Science degree in
microbiology from Emory University and is involved in the Scientific Committee
of the International Alliance for Biological Standardisation.

 

TVG has 12 vaccines currently under development targeting economically harmful
and zoonotic diseases. They include vaccines for protection against porcine
reproductive and respiratory syndrome, African swine fever, porcine
circovirus-2, streptococcus suis, bovine respiratory syncytial virus and lumpy
skin disease. TVG has also developed a transmissible candidate vaccine for
Lassa fever for use in the rodent reservoir. All vaccines are based on the
Company's tunable herpesvirus based platforms.

 

 

Jeremy Salt, Chief Executive of The Vaccine Group, said: "As we approach the
end of another successful year for TVG, it is especially positive that we can
look forward to gaining the support of three Board Advisors from January. Each
of them brings great expertise in their own areas. This will be really helpful
for TVG as we grow into a strong player in the global animal health innovation
sector."

 

The Vaccine Group statement ends

 

ENQUIRIES

 

 Frontier IP Group Plc                                                      T: 020 7332 2338
 Neil Crabb, Chief Executive Officer                                        neil@frontierip.co.uk

 Andrew Johnson, Communications and investor relations                      M: 07464 546 025

 andrew.johnson@frontierip.co.uk (mailto:andrew.johnson@frontierip.co.uk)

 Company website: www.frontierip.co.uk (http://www.frontierip.co.uk/)
 The Vaccine Group

 Jeremy Salt, Chief Executive Officer                                       jeremy.salt@thevaccinegroup.com

 Allenby Capital Limited (Nominated Adviser)                                T: 0203 328 5656

 Nick Athanas / George Payne

 

ABOUT THE VACCINE GROUP

The Vaccine Group (TVG) was founded in 2017 to develop and commercialise the
recombinant vaccine technology work of Dr Michael Jarvis, Associate Professor
in Virology and Immunology at the University of Plymouth's School of
Biomedical Sciences.

Through a mixed funding model of public grants and private equity, TVG has
established a pipeline of projects that address infectious diseases in animals
that are either zoonotic, transferred from animals to humans, or have a
serious commercial impact on livestock production, such as PRRS and African
Swine Fever in pigs, and bovine tuberculosis in cattle.

Most emerging infections, especially those with high pandemic potential in
humans, emerge from domestic and wildlife animal populations.

Due to the earlier ability to test animal vaccines in their intended host,
and the relative speed at which animal compared to human vaccines are approved
for use, vaccination of animals rather than humans is becoming accepted as
an approach to protect humans against some emerging zoonotic pathogens.

Its business model is to develop vaccine candidates to proof-of-concept with
commercial exploitation delivered through license agreements with vaccine
manufacturing companies.

For more information: www.thevaccinegroup.com (http://www.thevaccinegroup.com)

About Reach announcements

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKBBKBBDBKBD